Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
Using the technique of brain dialysis in freely moving rats we have investigated the effect of various dopamine (DA) receptor agonists on the release and metabolism of DA in two terminal dopaminergic areas, the nucleus accumbens and the dorsal caudate. Low doses of various DA receptor agonists such as apomorphine (12-100 micrograms/kg s.c.), LY 171555 (5-50 micrograms/kg s.c.), pergolide (5-25 micrograms/kg s.c.), (+)-3PPP (0.5-2.5 mg/kg s.c.) and BHT 920 (10-250 micrograms/kg s.c.) reduce DA release and elicit hypomotility. The potency of the drugs and their effectiveness is similar in the two areas. Inhibition of DA release appears related to the ability of the various agonists to stimulate D-2 rather than D-1 receptors. Thus, the reportedly selective D-1 agonist, SKF 38393, was inactive on DA release and metabolism even at doses fully active in eliciting D-1-mediated effects (grooming); on the other hand apomorphine, a D-1/D-2 agonist, and pergolide, a D-2 agonist with rather weak D-1 activity, reduced DA release in a manner which was related to their agonist activity at D-2 receptors; finally LY 171555, (+)-3PPP and BHT 920, which selectively stimulate D-2 receptors, were fully active at reducing DA release in vivo. Apomorphine, pergolide, LY 171555 and (+)-3PPP given at higher doses elicited behavioral stimulation. In contrast, BHT 920 failed to do so. In further contrast (-)-3PPP (0.1-10 mg/kg s.c.), which failed to reduce DA release at low doses, actually stimulated it at high doses (10 mg/kg s.c.) and elicited hypomotility, thus resembling DA receptor antagonists.(ABSTRACT TRUNCATED AT 250 WORDS)
Imperato
A
A
Institute of Experimental Pharmacology and Toxicology, University of Cigliari, Italy.
Tanda
G
G
Frau
R
R
Di Chiara
G
G
D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D001381:Azepines / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D001552:Benzazepines / Q000494:pharmacology; D001921:Brain / Q000378:metabolism*; D003956:Dialysis; D004298:Dopamine / Q000378:metabolism; D004873:Ergolines / Q000494:pharmacology; D006719:Homovanillic Acid / Q000378:metabolism; D007536:Isomerism; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009474:Neurons / Q000378:metabolism; D010479:Pergolide / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D019257:Quinpirole; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000378:metabolism*; D013997:Time Factors
D001381:Azepines; D001552:Benzazepines; D004873:Ergolines; D010880:Piperidines; D011954:Receptors, Dopamine; D015102:3,4-Dihydroxyphenylacetic Acid; D019257:Quinpirole; D010479:Pergolide; D015647:2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; C024763:talipexole; C026539:preclamol; D001058:Apomorphine; D004298:Dopamine; D006719:Homovanillic Acid